Trial Profile
A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Savolitinib (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- 20 Jul 2023 Status changed from active, no longer recruiting to discontinued due to inadequate accrual rate.
- 28 Jan 2023 Planned End Date changed from 24 Jan 2024 to 27 Jan 2024.
- 25 Jan 2023 Planned End Date changed from 31 Jan 2023 to 24 Jan 2024.